Press Release Sep 16 2022
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release regarding its tentative approval from the USFDA for Sugammadex Injection. The approval allows Zydus Pharmaceuticals (USA) Inc. to market the injection, which is used to reverse neuromuscular blockade during surgery. The drug will be produced at the company's manufacturing facility in Jarod, India.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Sep 13 2022
- Press Release Sep 12 2022
- Press Release Sep 09 2022
- Press Release Sep 07 2022
- Press Release Aug 31 2022
Later from Zydus Lifesciences
- Press Release Sep 20 2022
- Press Release Oct 01 2022
- Press Release Oct 03 2022
- Press Release Oct 04 2022
- Press Release Oct 06 2022
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences